文献速递眼底病与葡萄膜炎神经眼科角膜与眼表疾病

他莫昔芬与雷洛昔芬上市后眼部不良事件:基于人群的药物警戒研究

Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study.
PubMed 文献 · Retina · 2026-07-10

该研究利用FAERS数据库(2003年Q4至2025年Q2)分析他莫昔芬与雷洛昔芬的眼部不良事件信号。他莫昔芬报告4084例(平均年龄56.7岁),含505例眼部事件,以角膜移植排斥、球后出血等信号最强;雷洛昔芬报告5600例(平均年龄68.6岁),含437例眼部事件,以视网膜静脉血栓等血管事件信号突出。两者眼部不良事件谱不同,提示临床需关注。

要点

  • 他莫昔芬眼部信号以角膜移植排斥(ROR 118.9)、球后出血(104.6)等为主。
  • 雷洛昔芬眼部信号以视网膜静脉血栓(ROR 340.0)、视网膜血管血栓(133.8)等血管事件突出。
  • 两药眼部不良事件谱不同,需提高临床认识和前瞻性研究验证。

核心结论

  • 他莫昔芬与雷洛昔芬具有不同的眼部不良事件谱。
  • 他莫昔芬主要与视网膜、视神经和角膜疾病相关,雷洛昔芬则与视网膜血管及血栓栓塞事件强烈相关。
  • 研究结果强调临床医生认知的重要性及未来前瞻性研究的必要性。

研究设计与样本

  • 基于美国FDA不良事件报告系统(FAERS)的上市后药物警戒研究,数据范围2003年Q4至2025年Q2,使用OpenVigil 2.1分析。
  • 采用比例失衡分析计算报告比值比(ROR),比较药物-不良事件配对与所有其他药物。
  • 他莫昔芬相关不良事件报告4084例(平均年龄56.7岁),其中眼部不良事件505例。
  • 雷洛昔芬相关不良事件报告5600例(平均年龄68.6岁),其中眼部不良事件437例。

主要发现

  • 他莫昔芬最强信号包括角膜移植排斥(ROR 118.9)、球后出血(104.6)、眼静脉血栓(82.7)、视网膜沉积物(80.7)和黄斑裂孔(78.6)。
  • 他莫昔芬其他事件包括黄斑病变、视网膜病变和视神经病变。
  • 雷洛昔芬最突出信号为血管事件,包括视网膜静脉血栓(ROR 340.0)、视网膜血管血栓(133.8)、视网膜动脉血栓(54.9)和视网膜静脉阻塞(42.9)。
  • 雷洛昔芬其他事件包括视力下降、白内障、黄斑变性和青光眼。

关键数值与推荐

  • 他莫昔芬眼部不良事件信号:角膜移植排斥ROR 118.9,球后出血ROR 104.6,眼静脉血栓ROR 82.7,视网膜沉积物ROR 80.7,黄斑裂孔ROR 78.6。
  • 雷洛昔芬眼部不良事件信号:视网膜静脉血栓ROR 340.0,视网膜血管血栓ROR 133.8,视网膜动脉血栓ROR 54.9,视网膜静脉阻塞ROR 42.9。

临床怎么用

  • 使用他莫昔芬或雷洛昔芬的患者出现眼部症状时,应考虑药物相关不良事件可能。
  • 他莫昔芬使用者需关注视网膜、视神经和角膜相关病变。
  • 雷洛昔芬使用者需警惕视网膜血管及血栓栓塞事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tamoxifen and raloxifene are selective estrogen receptor modulators used for breast cancer treatment, and osteoporosis prevention. While systemic adverse events (AEs) are well recognized, ocular AEs have been less comprehensively characterized. The purpose of this study was to evaluate postmarketing ocular AEs associated with tamoxifen and raloxifene using a pharmacovigilance database. METHODS: The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) data from Q4 2003 to Q2 2025 were analyzed using OpenVigil 2.1. Disproportionality analyses were conducted to calculate reporting odds ratios (RORs) for drug-AE pairs compared with all other drugs. RESULTS: There were a total of 4,084 reports of AEs associated with tamoxifen (mean age 56.7 years), including 505 ocular AEs. The strongest signals were for corneal graft rejection (ROR 118.9), retrobulbar hemorrhage (104.6), ophthalmic vein thrombosis (82.7), retinal deposits (80.7), and macular hole (78.6). Additional events included maculopathy, retinopathy, and optic neuropathy. There were 5,600 reports of AEs associated with raloxifene (mean age 68.6 years), including 437 ocular AEs. The most prominent signals were vascular, including retinal vein thrombosis (ROR 340.0), retinal vascular thrombosis (133.8), retinal artery thrombosis (54.9), and retinal vein occlusion (42.9). Other events included reduced visual acuity, cataract, macular degeneration, and glaucoma. CONCLUSIONS: Tamoxifen and raloxifene had unique ocular AE profiles. Tamoxifen was primarily linked to retinal, optic nerve, and corneal disorders, whereas raloxifene was strongly associated with retinal vascular and thromboembolic events. These findings underscore the importance of clinician awareness and future prospective studies to further elucidate the risks.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Osba AA, Saleh F, Verma AV, et al. Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study. Retina. 2026. PMID: 42424405. doi:10.1097/IAE.0000000000004916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。